articleTop 1% cited
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Annals of Oncology · 2017 · Vol. 28(Suppl 4) · pp. iv119–iv142
John B.A.G. Haanen✉(The Netherlands Cancer Institute)Franck CarbonnelCaroline Robert(Institut Gustave Roussy)Keith M. KerrSolange Peters(University Hospital of Lausanne)James Larkin(Royal Marsden Hospital)Karin Jordan(University Hospital Heidelberg)
Cancer Immunotherapy and BiomarkersColorectal Cancer Treatments and StudiesCAR-T cell therapy researchMedicineOncologyInternal medicineImmunotherapyMetastatic breast cancerAdverse effectCancerBreast cancer
MeSH terms
Antineoplastic Agents, ImmunologicalIpilimumabNivolumabAntibodies, MonoclonalFollow-Up StudiesHumansMedical OncologyNeoplasmsAntibodies, Monoclonal, HumanizedDrug-Related Side Effects and Adverse Reactions
Citations
2,321
FWCI
106.32
field-weighted impact
References
90
Percentile
100%
vs. same field & year
Citations per year
Cited by
Association of Steroids Use with Survival in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
Cancers · 2020 · 290 citations
A review of cancer immunotherapy toxicity
CA A Cancer Journal for Clinicians · 2020 · 1,391 citations
Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations
Annals of Oncology · 2020 · 963 citations
Cytokines in clinical cancer immunotherapy
British Journal of Cancer · 2018 · 1,189 citations
Top 10 Challenges in Cancer Immunotherapy
Immunity · 2020 · 2,223 citations
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Journal of Clinical Oncology · 2018 · 3,616 citations
EASL Clinical Practice Guidelines: Drug-induced liver injury
Journal of Hepatology · 2019 · 1,079 citations
References
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
The Lancet Oncology · 2015 · 1,554 citations
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
New England Journal of Medicine · 2010 · 15,037 citations
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
New England Journal of Medicine · 2015 · 9,391 citations
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
The Lancet Oncology · 2015 · 1,421 citations
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Journal of Clinical Oncology · 2014 · 2,198 citations
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
The Lancet Oncology · 2015 · 2,648 citations
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
New England Journal of Medicine · 2015 · 8,491 citations
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
New England Journal of Medicine · 2012 · 12,531 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.